Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADTX Aditxt	$1.69 -0.6%	$2.90	$1.51 ▼ $27,200.00	$3.58M	1.6	789,956 shs	27,313 shs
ATAI Atai Life Sciences	$2.31 +4.5%	$1.52	$1.03 ▼ $2.57	$462.78M	1.22	1.60 million shs	2.93 million shs
STOK Stoke Therapeutics	$9.43 +2.7%	$8.32	$5.35 ▼ $17.58	$501.20M	1.2	710,656 shs	464,516 shs
YMAB Y-mAbs Therapeutics	$4.62 +4.8%	$4.38	$3.55 ▼ $16.11	$209.21M	0.53	312,056 shs	243,543 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADTX Aditxt	-2.30%	-6.59%	-26.09%	-91.50%	-99.99%
ATAI Atai Life Sciences	+7.28%	+7.80%	+51.37%	+27.75%	+37.27%
STOK Stoke Therapeutics	-1.92%	-8.66%	-5.94%	+11.00%	-36.29%
YMAB Y-mAbs Therapeutics	+2.08%	+4.26%	+7.56%	-19.96%	-63.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADTX Aditxt	0.5462 of 5 stars	0.0	3.0	0.0	2.7	0.0	0.6
ATAI Atai Life Sciences	2.1722 of 5 stars	3.7	1.0	0.0	2.0	2.5	0.6
STOK Stoke Therapeutics	3.9465 of 5 stars	3.6	2.0	4.8	3.0	1.7	0.0
YMAB Y-mAbs Therapeutics	3.7204 of 5 stars	4.4	2.0	0.0	3.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADTX Aditxt	0.00	N/A	N/A	N/A
ATAI Atai Life Sciences	3.33	Buy	$8.67	275.18% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	146.02% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$16.10	248.48% Upside

Current Analyst Ratings Breakdown

Latest YMAB, STOK, ADTX, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADTX Aditxt	$55.32K	64.76	N/A	N/A	$2,687.49 per share	0.00
ATAI Atai Life Sciences	$1.86M	248.41	N/A	N/A	$1.47 per share	1.57
STOK Stoke Therapeutics	$190.91M	2.70	N/A	N/A	$3.57 per share	2.64
YMAB Y-mAbs Therapeutics	$88.66M	2.36	N/A	N/A	$2.32 per share	1.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADTX Aditxt	-$32.38M	N/A	0.00	∞	N/A	N/A	-439.07%	-122.96%	N/A
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	$0.79	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	8/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.64	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	8/11/2025 (Estimated)

Latest YMAB, STOK, ADTX, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ADTX Aditxt	-$26,400.00	-$8.12	+$26,391.88	-$8.12	$0.43 million	$0.00 million
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADTX Aditxt	N/A	0.09	0.08
ATAI Atai Life Sciences	0.14	5.81	5.81
STOK Stoke Therapeutics	N/A	5.09	5.09
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADTX Aditxt	15.54%
ATAI Atai Life Sciences	28.41%
STOK Stoke Therapeutics	N/A
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ADTX Aditxt	0.01%
ATAI Atai Life Sciences	31.20%
STOK Stoke Therapeutics	11.30%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADTX Aditxt	60	2.12 million	14.23 million	No Data
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

YMAB, STOK, ADTX, and ATAI Headlines

Recent News About These Companies

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28 at 6:35 AM | globenewswire.com

Infinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 28 at 6:10 AM | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26 at 11:39 PM | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26 at 10:34 AM | quiverquant.com

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26 at 10:00 AM | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

HC Wainwright Brokers Decrease Earnings Estimates for YMAB

May 23, 2025 | marketbeat.com

HC Wainwright Brokers Reduce Earnings Estimates for YMAB

May 23, 2025 | americanbankingnews.com

FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 20, 2025 | marketbeat.com

HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00

May 20, 2025 | americanbankingnews.com

YMAB FY2025 EPS Forecast Raised by Cantor Fitzgerald

May 18, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus Target Price from Analysts

May 18, 2025 | americanbankingnews.com

Wedbush Cuts Earnings Estimates for Y-mAbs Therapeutics

May 17, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

May 17, 2025 | marketbeat.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Paradigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 16, 2025 | marketbeat.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMAB, STOK, ADTX, and ATAI Company Descriptions

Aditxt NASDAQ:ADTX

$1.69 -0.01 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.67 -0.02 (-1.18%)

As of 07:59 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Atai Life Sciences NASDAQ:ATAI

$2.31 +0.10 (+4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+1.08%)

As of 07:57 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Stoke Therapeutics NASDAQ:STOK

$9.43 +0.25 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$9.36 -0.07 (-0.74%)

As of 06:49 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.62 +0.21 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$4.62 +0.00 (+0.11%)

As of 04:04 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time